Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Sclerotherapy vs placebo

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 613 participants
Moderate

Sclerotherapy vs placebo

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 11.88 [4.54, 31.09]
3 studies · 528 participants
Moderate

Sclerotherapy vs placebo

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 4.06 [1.28, 12.84]
3 studies · 528 participants
Moderate

Sclerotherapy vs placebo

Pain ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Sclerotherapy vs placebo

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Very low

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Participant perception of change with treatment · adult men with premature ejaculation

SSRI probably leads to higher participant perception of change with treatment compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.92 [1.66, 2.23]
6 studies · 3260 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Participant satisfaction with intercourse · adult men with premature ejaculation

SSRI probably leads to higher participant satisfaction with intercourse compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.63 [1.42, 1.87]
3 studies · 4273 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Withdrawals due to adverse events · adult men with premature ejaculation

SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 3.8 [2.61, 5.51]
20 studies · 7367 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Perceived control over ejaculation · adult men with premature ejaculation

SSRI probably leads to higher perceived control over ejaculation compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 2.29 [1.72, 3.05]
3 studies · 4273 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Participant distress about PE · adult men with premature ejaculation

SSRI probably leads to higher participant distress about PE compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.54 [1.26, 1.88]
1 study · 652 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Adverse events · adult men with premature ejaculation

SSRI probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.71 [1.48, 1.99]
17 studies · 4624 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

IELT · adult men with premature ejaculation

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 5872 participants
Low